Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $57.00 USD
Change Today +1.40 / 2.52%
Volume 200.0
As of 8:10 PM 03/30/15 All times are local (Market data is delayed by at least 15 minutes).

koninklijke dsm nv (KDSKF) Snapshot

Open
$57.00
Previous Close
$55.60
Day High
$57.00
Day Low
$57.00
52 Week High
07/3/14 - $72.14
52 Week Low
01/15/15 - $49.50
Market Cap
10.3B
Average Volume 10 Days
490.4
EPS TTM
--
Shares Outstanding
181.4M
EX-Date
05/5/15
P/E TM
--
Dividend
$1.79
Dividend Yield
4.07%
Current Stock Chart for KONINKLIJKE DSM NV (KDSKF)

Related News

No related news articles were found.

koninklijke dsm nv (KDSKF) Related Businessweek News

View More BusinessWeek News

koninklijke dsm nv (KDSKF) Details

Koninklijke DSM N.V. operates as a life sciences and materials sciences company worldwide. The company operates through Nutrition, Performance Materials, Polymer Intermediates, and Innovation Center segments. It manufactures food enzymes, cultures, yeast extracts, savory ingredients, and other specialty ingredients for the food and beverage industries; and nutritional products, such as vitamins, carotenoids, eubiotics, feed enzymes, premixes, minerals, and nutritional lipids, as well as active and performance ingredients for the feed, food, pharmaceutical, and personal care industries. The company also offers Dyneema, a strong fiber; specialty plastics that are used in components for the electrical and electronic, automotive, flexible food packaging, and consumer goods industries; and resins solutions for paints and coatings, composite materials, and fiber optic coatings. In addition, it produces fiber intermediates, such as caprolactam, which is used as raw material for polyamide 6; acrylonitrile that is used as a raw material for acrylic fibers, plastics, rubber, water treatment chemicals, and various specialty products; and other products, including ammonium sulfate, sodium cyanide, cyclohexanone, diaminobutane, pyrrolidine, and acetonitrile. Further, the company provides bio-based chemicals and materials; KhepriCoat, which enables glass to transmit light for use in solar energy and lighting industries, as well as in horticultural and agricultural greenhouses; and develops and produces materials, as well as components, sub-assemblies, and medical devices for its customers. Koninklijke DSM N.V. was founded in 1902 and is headquartered in Heerlen, the Netherlands.

21,351 Employees
Last Reported Date: 03/3/15
Founded in 1902

koninklijke dsm nv (KDSKF) Top Compensated Officers

Chairman of the Managing Board and Chief Exec...
Total Annual Compensation: €1.2M
Chief Financial Officer and Member of the Man...
Total Annual Compensation: €630.0K
Member of the Managing Board
Total Annual Compensation: €754.0K
Member of the Managing Board
Total Annual Compensation: €724.0K
Member of Managing Board
Total Annual Compensation: €724.0K
Compensation as of Fiscal Year 2014.

koninklijke dsm nv (KDSKF) Key Developments

Evonik Reportedly Mulls Takeover Bid For Clariant And Other Firms

Evonik Industries AG (DB:EVK) is considering a takeover bid for Clariant AG (SWX:CLN), according to people familiar with the matter. "Evonik is considering a bid for Swiss peer Clariant to create a group with a market value of more than €20 billion ($22 billion),” but several sources familiar with the situation said it had also looked at Koninklijke DSM N.V. (ENXTAM:DSM) and Croda International plc (LSE:CRDA). Two of the sources said that work on a potential Clarianttie-up had passed a purely exploratory stage, while another source said that Clariant had not received any bid from Evonik. "Has someone leaked it to kill the deal at an early stage? "a source familiar with Evonik's thinking said, adding thatClariant and its owners had not been receptive to approaches from peers. Evonik has been reviewing options in recent months, these people said, as the German company has been looking to join the wave of M&A in the chemicals sector. Evonik said it did not comment on any market rumours. Clariant and CVC declined to comment.

Royal DSM Announces Departure of Stefan Doboczky as Managing Board Member on June 1, 2015

Royal DSM announced the departure of DSM Managing Board member Stefan Doboczky per 1 June 2015. The responsibilities of Stefan Doboczky will be redistributed among the current Managing Board members.

DSM and CVC Capital Partners Announce Partnership for Polymer Intermediates and Composite Resins Through Formation of New Company

Royal DSM and CVC Capital Partners announced a partnership for DSM's activities in Polymer Intermediates (Caprolactam and Acrylonitrile) and Composite Resins through the formation of a new company, provisionally called NewCo. NewCo will be 65% owned by CVC and 35% by DSM, with 1,950 employees. Pro-forma third-party sales of NewCo in 2014 amounted to EUR 2.1 billion with a 2014 EBITDA of EUR 106 million. The enterprise value of the transaction is EUR 600 million plus an earn-out of up to EUR 175 million. Financing of NewCo will primarily be through an equity contribution from both shareholders, third party financing and a EUR 100 million bridge loan provided by DSM. Estimated net cash proceeds at closing to DSM of EUR 300-350 million. DSM will recognize an initial book loss of approximately EUR 130 million after tax and non-controlling interests, as an exceptional item in first quarter of 2015. Closing, subject to customary conditions and approvals, is expected in third quarter of 2015. DSM will contribute its global caprolactam business (Europe, North America, its 60% stake in DNCC (China) and the caprolactam licensing business), DSM's acrylonitrile business and DSM's Composite Resins business including its 75% stake in JDR (China). DSM's 65% stake in the service organization Sitech Services held via its caprolactam and acrylonitrile businesses will also be transferred. DSM Engineering Plastics has secured at least 80% of its caprolactam needs for 15 years after closing via drawing rights to secure its strategic position and competitiveness, effectively maintaining DSM Engineering Plastics' backward integration. For DSM, this proposed transaction is a logical step in the execution of its strategy as Polymer Intermediates (caprolactam, acrylonitrile) and Composite Resins no longer fit with its more resilient portfolio in Nutrition and Performance Materials. The partnership with CVC allows DSM to further reduce the cyclicality of its portfolio, secure a long-term competitive supply position of caprolactam for DSM Engineering Plastics and fully focus on the Nutrition, Performance Materials and Innovation activities complemented by accelerated actions to improve efficiencies and reduce costs. CVC will work with current management of these businesses to make NewCo a success. CVC sees these businesses as a solid platform with leading positions and substantial potential for future growth. As a 35% shareholder in NewCo, DSM will be able to benefit from any improvements in the businesses that will become part of NewCo. NewCo will continue to supply at least 80% of DSM Engineering Plastics' caprolactam needs in Europe and North America for the coming 15 years via a drawing rights contract, effectively maintaining DSM Engineering Plastics' backward integration. In China DSM Engineering Plastics will continue to be supplied by NewCo. This secures an ongoing strategic and competitive position for the polyamide 6 business in which DSM is a global leader. NewCo will operate as an independent company with three business units: caprolactam, acrylonitrile and composite resins. Pro-forma third party sales of NewCo amounted to EUR 2.1 billion in 2014 with an EBITDA of EUR 106 million, excluding non-controlling interests (DNCC, JDR and Sitech) of EUR 19 million and including the caprolactam licensing income. Due to the ownership change of DSM's caprolactam and acrylonitrile businesses, NewCo automatically becomes an indirect 65% shareholder in Sitech Services, the on-site service provider at the Chemelot Industrial Park in Sittard-Geleen (Netherlands). As a service provider, Sitech generally reinvests the majority of its profit into the Chemelot Industrial Park. DSM will remain a 5% shareholder in Sitech Services via DSM Engineering Plastics.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
KDSKF:US $57.00 USD +1.40

KDSKF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Ashland Inc $128.71 USD +1.18
Celanese Corp $56.17 USD +1.14
Grupo Bimbo SAB de CV $43.13 MXN +0.51
Kerry Group PLC €62.43 EUR +0.12
Solvay SA €134.40 EUR -1.25
View Industry Companies
 

Industry Analysis

KDSKF

Industry Average

Valuation KDSKF Industry Range
Price/Earnings 59.1x
Price/Sales 0.9x
Price/Book 1.4x
Price/Cash Flow 58.4x
TEV/Sales 0.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact KONINKLIJKE DSM NV, please visit www.dsm.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.